Panel to Review Insmed Lung Disease Drug
Federal Register notice: FDA has announced an 8/7 Antimicrobial Drugs Advisory Committee meeting. Panel members will discuss an Insmed NDA for amikacin liposome inhalation suspension, indicated for treating nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex in adults as part of a combination antibacterial drug regimen. To view the notice, click here.